Importantly, preclinical models showed that inhibition of the PI3K pathway impairs survival of NSCLC cells harboring PIK3CA gene alterations [10]–[11], and numerous novel PI3K, Akt and mTOR inhibitors have entered clinical trial testing for the treatment of PI3K-addicted cancers. This evidence concerns the gene PIK3CA and non-small cell lung carcinoma.